Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. News
  7. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Solution Biologics Sdn Bhd Signs Finished Product and a Bulk Product Agreement with Cansino Biologics Inc for the Supply of the Recombinant Ad5-Ncov Vaccine for Use Against the Covid-19 Virus

07/30/2021 | 01:07am EDT

Solution Group Berhad's wholly-owned subsidiary, Solution Biologics Sdn Bhd, has signed a finished product and a bulk product agreement with CanSino Biologics Inc. for the supply of the Recombinant Ad5-nCoV vaccine for use against the COVID-19 virus. The finished product agreement allows SOLBIO to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia. Meanwhile, the bulk agreement will see CanSino supply the active pharmaceutical ingredients for the fill and finish ("F&F") to SOLBIO. Both agreements come with a period of ten (10) years with immediate effect.


ę S&P Capital IQ 2021
All news about CANSINO BIOLOGICS INC.
09/10Cansino Biologics Inc. Announces Executive Changes
CI
09/07CANSINO BIOLOGICS : Indonesia approves J&J, Cansino COVID-19 vaccines for emergency use
RE
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
09/06CORONAVIRUS PANDEMIC : Chinese developer shares efficacy of inhaled vaccines
PU
08/27CANSINO BIOLOGICS : COVID shot drives CanSinoBIO's first six-month profit since at least 2..
RE
08/27Cansino Biologics Inc. Reports Audited Consolidated Earnings Results for the Six Months..
CI
08/13Certain A Shares of CanSino Biologics Inc. are subject to a Lock-Up Agreement Ending on..
CI
08/13CANSINO BIOLOGICS INC.(SHSE : 688185) added to Shanghai Stock Exchange A Share Index
CI
08/13CANSINO BIOLOGICS INC.(SHSE : 688185) added to Shanghai Stock Exchange Composite Index
CI
08/06CANSINO BIOLOGICS : CanSinoBIO COVID-19 says booster shot can reverse drop in antibodies
RE
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Financials
Sales 2021 9 984 M 1 545 M 1 545 M
Net income 2021 5 282 M 817 M 817 M
Net cash 2021 5 073 M 785 M 785 M
P/E ratio 2021 11,5x
Yield 2021 0,00%
Capitalization 70 144 M 10 850 M 10 851 M
EV / Sales 2021 6,52x
EV / Sales 2022 2,26x
Nbr of Employees 726
Free-Float 37,1%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | 6185 | CNE100003F01 | MarketScreener
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 231,34 CNY
Average target price 308,77 CNY
Spread / Average Target 33,5%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.57.85%10 850
CSL LIMITED10.32%103 374
WUXI BIOLOGICS (CAYMAN) INC.18.19%66 169
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 198
BIOGEN INC.18.16%43 118
ALEXION PHARMACEUTICALS, INC.0.00%40 336